Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Mouth Neoplasms 3Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Skin Neoplasms 2Recurrence 2Mycosis Fungoides 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Laryngeal Neoplasms 2Vaccinia 1Sinonasal Squamous Cell Carcinoma 1Sarcoma 1Resectable Non-small Cell Lung Cancer 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Immunoblastic Lymphadenopathy 1

Interventions

cemiplimab 1Pemetrexed 1Paclitaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Resectable Non-small Cell Lung Cancer × cemiplimab × 30 days × Clear all
NCT06161441 2026-05-28

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
195 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡